Literature DB >> 11819800

Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

L Zhuang1, J You, B Z Tang, S Y Ding, K H Yan, D Peng, Y M Zhang, L Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11819800      PMCID： PMC4688732          DOI： 10.3748/wjg.v7.i3.407

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


× No keyword cloud information.
  20 in total

1.  Study on the quality of recombinant proteins using matrix-assisted laser desorption ionization time of flight mass spectrometry.

Authors:  Guo-Hua Zhou; Guo-An Luo; Ya-Cheng Cao; Ming-Sheng Zhu
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

2.  Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B.

Authors:  S Hadziyannis; T Bramou; A Makris; G Moussoulis; L Zignego; C Papaioannou
Journal:  J Hepatol       Date:  1990       Impact factor: 25.083

3.  A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg.

Authors:  G Fattovich; P Farci; M Rugge; L Brollo; A Mandas; P Pontisso; G Giustina; M E Lai; F Belussi; G Busatto
Journal:  Hepatology       Date:  1992-04       Impact factor: 17.425

4.  Establishment of a nonradioactive assay for 2'-5' oligoadenylate synthetase and its application in chronic hepatitis C patients receiving interferon-alpha

Authors:  Wen-Bin Tong; Chun-Ying Zhang; Bai-Fang Feng; Qi-Min Tao
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

Review 5.  Thymosins: structure, function and therapeutic applications.

Authors:  T L Low; A L Goldstein
Journal:  Thymus       Date:  1984

6.  Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus.

Authors:  G Marinos; F Torre; S Chokshi; M Hussain; B E Clarke; D J Rowlands; A L Eddleston; N V Naoumov; R Williams
Journal:  Hepatology       Date:  1995-10       Impact factor: 17.425

7.  A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.

Authors:  P Andreone; C Cursaro; A Gramenzi; C Zavagliz; I Rezakovic; E Altomare; R Severini; J S Franzone; O Albano; G Ideo; M Bernardi; G Gasbarrini
Journal:  Hepatology       Date:  1996-10       Impact factor: 17.425

8.  Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe.

Authors:  F Bonino; F Rosina; M Rizzetto; R Rizzi; E Chiaberge; R Tardanico; F Callea; G Verme
Journal:  Gastroenterology       Date:  1986-05       Impact factor: 22.682

9.  Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

Authors:  G Pastore; T Santantonio; M Milella; L Monno; N Mariano; R Moschetta; L Pollice
Journal:  J Hepatol       Date:  1992-03       Impact factor: 25.083

Review 10.  Immune response to hepatitis B virus proteins: relevance of the murine model.

Authors:  D R Milich
Journal:  Semin Liver Dis       Date:  1991-05       Impact factor: 6.115
View more
  10 in total

1.  Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine.

Authors:  Xiao-Ju Guan; Xiao-Jun Guan; Yu-Zhang Wu; Zheng-Cai Jia; Tong-Dong Shi; Yan Tang
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

2.  Anti-HBV hairpin ribozyme-mediated cleavage of target RNA in vitro.

Authors:  Yu-Hu Song; Ju-Sheng Lin; Nan-Zhi Liu; Xin-Juan Kong; Na Xie; Nan-Xia Wang; You-Xin Jin; Kuo-Huan Liang
Journal:  World J Gastroenterol       Date:  2002-02       Impact factor: 5.742

3.  Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization.

Authors:  Yui-Jie Bai; Jin-Rong Zhao; Guan-Ting Lv; Wen-Hong Zhang; Yan Wang; Xiao-Jun Yan
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

4.  Advances in the Treatment of Hepatitis B and Hepatitis C Nonresponders: A Report of Symposia Presented at the 15th Conference of the Asian Pacific Association for the Study of the LiverAugust 18-21, 2005Bali, Indonesia.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

5.  Hepatoprotective role of Ganoderma lucidum polysaccharide against BCG-induced immune liver injury in mice.

Authors:  Guo-Liang Zhang; Ye-Hong Wang; Wei Ni; Hui-Ling Teng; Zhi-Bin Lin
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

6.  Anti-HBV effect of TAT- HBV targeted ribonuclease.

Authors:  Jin Ding; Jun Liu; Cai-Fang Xue; Wei-Dong Gong; Ying-Hui Li; Ya Zhao
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

7.  Sequential changes of serum ferritin levels and their clinical significance in lamivudine-treated patients with chronic viral hepatitis B.

Authors:  Zheng-Wen Liu; Qun-Ying Han; Ni Zhang; Wen Kang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

8.  A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma.

Authors:  Chun-Hong Ma; Wen-Sheng Sun; Pei-Kun Tian; Li-Fen Gao; Su-Xia Liu; Xiao-Yan Wang; Li-Ning Zhang; Ying-Lin Cao; Li-Hui Han; Xiao-Hong Liang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

9.  HBV cccDNA in patients' sera as an indicator for HBV reactivation and an early signal of liver damage.

Authors:  Ying Chen; Johnny Sze; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

10.  Changes in serum and histology of patients with chronic hepatitis B after interferon alpha-2b treatment.

Authors:  Hong-Lei Han; Zhen-Wei Lang
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.